A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus - Trial SLCTR_2015_002
Access comprehensive clinical trial information for SLCTR_2015_002 through Pure Global AI's free database. This Phase 3 trial is sponsored by Anthera Pharmaceuticals, Inc and is currently Suspended. The study focuses on Systemic Lupus Erythematosus.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
SLCTR_2015_002
Phase 3
Suspended
Trial Details
Sri Lanka Clinical Trials Registry • SLCTR_2015_002
A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus
Study Focus
Interventional
Sponsor & Location
Anthera Pharmaceuticals, Inc
Belarus, Brazil, Colombia, Georgia, Guatemala, HongKong, North Korea, Malaysia, Mexico, Philippines,
Timeline & Enrollment
Phase 3
Apr 09, 2015
N/A
ICD-10 Classifications
Systemic lupus erythematosus
Systemic lupus erythematosus, unspecified
Lupus erythematosus
Systemic lupus erythematosus with organ or system involvement
Other forms of systemic lupus erythematosus
Data Source
Sri Lanka Clinical Trials Registry
SLCTR_2015_002
Non-Device Trial